Loading…
← CockpitCompetitor Analysis › COH.AX Cochlear LimitedOpen in the cockpit ↗

Cochlear LimitedCOH.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical Specialties

World's leading maker of cochlear implants, restoring hearing for people with severe hearing loss.

≈ A mini-Medtronic focused solely on cochlear implantsMomentum leader 96
Mkt cap
$6.72B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$33.7M
20-day average traded
Fwd P/E
29.1×
forward earnings
ROIC−WACC
+2.4 pp
WACC 9.5%
Hurdle
+15 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · AUDA$153.17
1D+0.4%
1W+1.6%
1M+9.9%
3M+13.1%
6M+57.8%
YTD-41.2%
1Y-43.1%
ATR %2.8%
52w lowhigh46.2% off high

What Cochlear does

World's leading maker of cochlear implants, restoring hearing for people with severe hearing loss.

Sells an implant fitted once by surgery, then earns again as recipients upgrade the external sound processor every few years, a recurring line that rests on its installed base. Government and insurance reimbursement pays for most devices, so public tenders and coverage decisions matter. Most sales are outside Australia.

In one line: A mini-Medtronic focused solely on cochlear implants.

Products and services

  • Cochlear implant systems
  • Sound processor upgrades
  • Bone conduction implants (Baha)
  • Acoustic implants

Customers

  • Hospitals/ENT surgeons
  • Patients with severe hearing loss
  • Health insurers/government payers

Where it sits in the supply chain

  • Medical devices
  • Implantable hearing devices
  • Cochlear implants + sound processors

What could go right

  • Growing global hearing-loss treatment penetration
  • Upgrade cycle for existing recipients

What could go wrong

  • Reimbursement/funding policy risk
  • Currency exposure (AUD reporting, global sales)

Moat: wide (IP / patents, regulatory licence, switching costs). Global installed-base leadership, deep surgeon relationships and patent-protected implant technology.

Headquarters: Sydney, Australia · Founded: 1981 · Employees: 5,400

Named competitors

Cochlear at a glance

Size Cochlear (COH.AX) is an Australia Health Care company (Medical Specialties) with a market value of $6.72B, the 50th largest of 317 Australia companies the cockpit tracks. Shares closed at A$153.17 on 18 Nov 2026.

Performance Over six months the shares gained 57.8%, against +25.7% for the median peer and +1.2% for the Australia market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 0.9% over the last twelve months (peer median +8.1%); the operating margin is 12.9% (peer median 17.3%).

Valuation It trades at 29.1× forward earnings against a peer median of 20.8× (5th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.4 points above its cost of capital (9.5% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026COH.AX 158Peer median 127
Six months, rebased to 100: Cochlear against the median of its 20 peers (local-currency closes).

Cochlear financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$2.33BA$2.33BA$2.36BA$2.26BA$1.96B
Revenue growth—-1%+4%+15%—
Gross profitA$1.65BA$1.65BA$1.74BA$1.70BA$1.47B
EBITDAA$407MA$407MA$600MA$606MA$493M
Net incomeA$147MA$147MA$389MA$357MA$301M
Free cash flowA$307MA$307MA$175MA$326MA$312M
Capital expenditureA$90.7MA$90.7MA$103MA$89.8MA$95.9M
Total debtn/aA$213MA$236MA$244MA$202M

Quarterly statements and history in the cockpit →

Cochlear competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%+20%LNTHCTECYPSNTFX7747BLCOGETI-B6886176869HAE7701LIVNMMSIGMED300677DIAMMEDBRKRPODDCOH.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Cochlear is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%15×20×25×30×LNTHCTECYPSNTFX7747BLCOGETI-B6886173008326869HAE7701LIVNGMED300677DIAMMEDBRKRPODDCOH.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cochlear is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%LNTHCTECTFX7747BLCOGETI-B6886173008326869HAELIVNGMED300677DIABRKRPODDCOH.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cochlear is the large dot.

Cochlear competitors and peer comparison

Head to head with its named competitors (COH.AX vs SOON.SW vs DEMANT.CO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cochlear COH.AX$6.72B+58%-1%13%29.1×23.9%
Sonova SOON.SW$19.8B+40%-6%23%25.3×6.0%
Demant A/S DEMANT.CO$10.4B+39%+10%18%23.2×5.8%

How Cochlear compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cochlear against its 20 peers (data as of 18 Nov 2026)
MeasureCOH.AXPeer medianRank in peer set
1-month return+9.9%+12.8%10th lowest of 21
6-month return+57.8%+25.7%3rd highest of 21
Distance from 52-week high-46.2%-6.1%2nd lowest of 21
Revenue growth (TTM)-0.9%+8.1%5th lowest of 21
Operating margin12.9%17.3%4th lowest of 21
Forward P/E29.1×20.8×5th most expensive of 21
Growth the price implies (Req g, 7 yrs)23.9%9.8%2nd most demanding of 19
Growth delivered (Del g)+9.3%+9.7%9th lowest of 19
Hurdle (Req g minus delivered)+14.6 pp+1.4 pp2nd most demanding of 19
ROIC minus cost of capital+2.4 pp+3.5 pp7th lowest of 21
EV / EBITDA24.7×14.0×most expensive of 18
Net debt / EBITDA0.1×0.9×8th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%

Questions

Who are Cochlear's main competitors?
Named competitors: Sonova (Advanced Bionics) (SOON.SW), Demant (Oticon Medical) (DEMANT.CO), MED-EL (private or unlisted). The cockpit's measured peer set (industry) also includes Lantheus (LNTH), ConvaTec (CTEC.L), Ypsomed (YPSN.SW), Teleflex (TFX), Asahi Intecc (7747.T), Bausch + Lomb (BLCO.TO).
Is Cochlear expensive compared with its peers?
On forward p/e it trades at 29.1× against a peer median of 20.8×, 5th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Cochlear stock performed?
Over six months to 18 Nov 2026 the shares returned +57.8% against +25.7% for the median peer; over one year -43.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.